vimarsana.com

Page 6 - வசந்த வாழ்க்கை அறிவியல் தொடர்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pharming Reports on Annual General Meeting of Shareholders

Pharming Reports on Annual General Meeting of Shareholders LEIDEN, The Netherlands, May 19, 2021 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved. As a result, Sijmen de Vries was reappointed for four years as Chief Executive Officer and an Executive Director of the Board of Directors. In addition, further to the announcement on 23 March 2021, Jabine van der Meijs, Steven Baert and Leonard Kruimer have been appointed as Non-Executive Directors to the Board of Directors and Aad de Winter and Barrie Ward have retired from the Board of Directors, effective immediately.

Pharming Group reports financial results for the first quarter of 2021

Pharming Group reports financial results for the first quarter of 2021 Results impacted by effects of COVID-19 in the US; recovery towards the end of Q1 2021 with expected return to growth in Q2 2021 LEIDEN, Netherlands, May 13, 2021 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its (unaudited) financial report for the first quarter of the year ended 31 March 2021. As previously announced, as of 1 January 2021, Pharming changed its presentation currency from Euro to US Dollars. The Company will hold an analyst conference call at 13.30 CET/07.30 EST today. Dial in details can be found on page 6 of this report

Intravacc announces positive preclinical data for its SARS-CoV-2 nose spray vaccine

Share this article Share this article BILTHOVEN, Netherlands, April 7, 2021 /PRNewswire/  Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has obtained positive preclinical results for its SARS-CoV-2 Outer Membrane Vesicle (OMV) based recombinant Spike protein (rSp) candidate nose spray vaccine. For the preclinical study four groups of mice and four groups of hamsters received two intranasal immunizations on day one and day 21. One group of mice and hamsters received a vaccine based on OMV s mixed with rSp (CovOMV) and the other a vaccine based on OMV s coupled to rSp based on Intravacc s proprietary OMV click technology (CovOMVclick). Control animals received respectively only OMV s or only rSp. On day 35 the mice blood samples were tested for virus neutralizing antibodies. The hamsters were challenged with SARS-CoV-2 on day 42 after blood collection. Over a period of seven days after challenges, thei

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.